DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prostascint (Capromab Pendetide) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

Drug Interactions

The effect of surgical and/or medical androgen ablation on the imaging performance of Indium In 111 ProstaScint® has not been studied. Preliminary data suggest hormone ablation may increase PSMA expression, with concurrent decrease in tumor expression of PSA.3 The use of ProstaScint® in this patient population cannot be recommended at this time.

OVERDOSAGE

The maximum amount of Indium In 111 ProstaScint® (capromab pendetide) that can be safely administered has not been determined. In clinical studies, single doses of 10 mg of Indium In 111 ProstaScint® were administered to 20 patients with prostate cancer; the type and frequency of adverse reactions at this dose were similar to those observed with lower doses. The maximum Indium In 111 dose administered with ProstaScint® in a clinical study was 6.5 mCi.

CONTRAINDICATIONS

Indium In 111 ProstaScint® (capromab pendetide) should not be used in patients who are hypersensitive to this or any other product of murine origin or to Indium In 111 chloride.

REFERENCES

  • 1.Kocher, DC: Radioactive decay data tables. DOE/TIC 115:11026, 1981.
  • 2.Data supplied by Oak Ridge Associated Universities. Radiopharmaceutical Internal Dose Information Center, 1984.
  • 3.Wright, GL, Jr; et al. Expression of Prostate-Specific Membrane Antigen in Normal, Benign, and Malignant Prostate Tissues. Urol Oncol. 1995; 1:18-28.


Jazz Pharmaceuticals, Inc. Customer Service: 1-(800) 833-3533

Manufactured by Jazz Pharmaceuticals, Inc.
Palo Alto, CA 94304
U.S. License No. 1901

ProstaScint® is a registered trademark of
Jazz Pharmaceuticals, Inc.

Printed in USA   PROSp-14-01
Revised 12/2010

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017